{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:34:58Z","timestamp":1791909298285,"version":"4.3.4"},"reference-count":251,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020475","name":"Directorate for STEM Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is distinguished by negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), making it an aggressive subtype of breast cancer and contributes to 15-20% of the total incidence. TNBC is a diverse disease with various genetic variations and molecular subtypes. The tumor microenvironment involves multiple cells, including immune cells, fibroblast cells, extracellular matrix (ECM), and blood vessels that constantly interact with tumor cells and influence each other. The ECM undergoes significant structural changes, leading to induced cell proliferation, migration, adhesion, invasion, and epithelial-to-mesenchymal transition (EMT). The involvement of EMT in the occurrence and development of tumors through invasion and metastasis in TNBC has been a matter of concern. Therefore, EMT markers could be prognostic predictors and potential therapeutic targets in TNBC. Chemotherapy has been one of the primary options for treating patients with TNBC, but its efficacy against TNBC is still limited. Targeted therapy is a critical emerging option with enhanced efficacy and less adverse effects on patients. Various targeted therapy approaches have been developed based on the specific molecules and the signaling pathways involved in TNBC. These include inhibitors of signaling pathways such as TGF-\u03b2, Wnt\/\u03b2-catenin, Notch, TNF-\u03b1\/NF-\u03baB and EGFR, as well as immune checkpoint inhibitors, such as pembrolizumab, 2laparib, and talazoparib have been widely explored. This article reviews recent developments in EMT in TNBC invasion and metastasis and potential targeted therapy strategies.<\/jats:p>","DOI":"10.3389\/fonc.2024.1431418","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T07:59:59Z","timestamp":1728547199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Mazharul","family":"Haque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritis K.","family":"Shyanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40364-021-00310-y","article-title":"Epidemiological trends of women\u2019s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study","volume":"9","author":"Yi","year":"2021","journal-title":"biomark Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules23092193","article-title":"Targeting breast cancer stem cells to overcome treatment resistance","volume":"23","author":"Palomeras","year":"2018","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of triple negative breast cancer, Seminars in cancer biology","volume":"72","author":"Borri","year":"2021","journal-title":"Elsevier"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v127.19","article-title":"Delays in breast cancer care by race and sexual orientation: results from a national survey with diverse women in the United States","volume":"127","author":"Poteat","year":"2021","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v110:4","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African\u2013American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute\u2019s Surveillance, Epidemiology, and end results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New Engl J Med"},{"key":"B13","article-title":"A cohort study of the variations in stage of initial presentation of breast cancer by age, deprivation and ethnicity in England 2019\u20132023","author":"Palmieri","year":"2019","journal-title":"Deprivation Ethnicity Engl"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-020-00169-z","article-title":"RDGN-based predictive model for the prognosis of breast cancer","volume":"9","author":"Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discovery"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer","volume":"54","author":"Kumar","year":"2023","journal-title":"J Advanced Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.7150\/ijbs.78554","article-title":"Chemical-proteomics identify peroxiredoxin-1 as an actionable target in triple-negative breast cancer","volume":"19","author":"Sp\u00ednola-Lasso","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40164-022-00361-3","article-title":"Increased expression of ECT2 predicts the poor prognosis of breast cancer patients","volume":"11","author":"Yi","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Are cancer cells really softer than normal cells","volume":"109","author":"Alibert","year":"2017","journal-title":"Biol Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.10.014","article-title":"Translating extracellular matrix: From cancer progression to therapeutics","volume":"62","author":"Karamanos","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"eabn7571","DOI":"10.1126\/scitranslmed.abn7571","article-title":"Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin","volume":"14","author":"Grasset","year":"2022","journal-title":"Sci Trans Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"a003277","DOI":"10.1101\/cshperspect.a003277","article-title":"TGF-\u03b2 biology in mammary development and breast cancer","volume":"3","author":"Moses","year":"2011","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGF\u03b2 in cancer","volume":"134","author":"Massagu\u00e9","year":"2008","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"151076","DOI":"10.1016\/j.ejcb.2020.151076","article-title":"Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF-\u03b2\/Smad4 axis driving the cells towards lethal EMT","volume":"99","author":"Faheem","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.04.010","article-title":"Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer","volume":"12","author":"Martin","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2330","article-title":"Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis","volume":"71","author":"Casas","year":"2011","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.168625","article-title":"Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition","volume":"286","author":"Dave","year":"2011","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-010-9175-z","article-title":"Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 hi\/CD24 lo\/-stem cell phenotype in human breast cancer","volume":"15","author":"Blick","year":"2010","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2347","article-title":"Small non-coding RNAs in animal development","volume":"9","author":"Stefani","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.62","article-title":"PKC\u03bb\/\u03b9 signaling promotes triple-negative breast cancer growth and metastasis","volume":"21","author":"Paul","year":"2014","journal-title":"Cell Death Differentiation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/35019573","article-title":"The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42","volume":"2","author":"Joberty","year":"2000","journal-title":"Nat Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.1038\/srep12520","article-title":"PKC\u03b6 promotes breast cancer invasion by regulating expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NF\u03baB-p65","volume":"5","author":"Paul","year":"2015","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201306088","article-title":"Twist1-induced dissemination preserves epithelial identity and requires E-cadherin","volume":"204","author":"Shamir","year":"2014","journal-title":"J Cell Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrg840","article-title":"Molecular mechanisms of tubulogenesis","volume":"3","author":"Hogan","year":"2002","journal-title":"Nat Rev Genet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3748\/wjg.v18.i7.601","article-title":"Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon","volume":"18","author":"Sipos","year":"2012","journal-title":"World J Gastroenterol: WJG"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.3390\/cancers14194845","article-title":"Regulation of TGF-\u03b2 1-induced EMT by autophagy-dependent energy metabolism in cancer cells","volume":"14","author":"Hwang","year":"2022","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2212negative breast cancer therapy: Current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B49","article-title":"Anthracycline medications (doxorubicin)","author":"Douedi","year":"2019"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(80)90352-7","article-title":"Combined chemotherapy and radiotherapy for locally advanced breast cancer","volume":"16","author":"Rubens","year":"1980","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"104404","DOI":"10.1016\/j.yexmp.2020.104404","article-title":"The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer","volume":"114","author":"Seltzer","year":"2020","journal-title":"Exp Mol Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2015.4.issue-7","article-title":"Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy","volume":"4","author":"Leone","year":"2015","journal-title":"Cancer Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"pky062","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19130","article-title":"Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012","volume":"319","author":"Plevritis","year":"2018","journal-title":"Jama"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3478","article-title":"Immune gene expression is associated with genomic aberrations in breast cancer","volume":"77","author":"Safonov","year":"2017","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cells9061392","article-title":"The roles of cancer stem cells and therapy resistance in colorectal carcinoma","volume":"9","author":"Das","year":"2020","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1150861","article-title":"Doxorubicin resistance in breast cancer is mediated via the\nactivation of FABP5\/PPAR\u03b3 and CaMKII signaling pathway","volume":"14","author":"Chen","year":"2023","journal-title":"Front\nPharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/febs.v288.21","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","volume":"288","author":"van der Zanden","year":"2021","journal-title":"FEBS J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic Malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Internal Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4 + 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","article-title":"Pharmacologic resistance in colorectal cancer: a review","volume":"8","author":"Hammond","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"B65","volume-title":"Cancer chemotherapy: basic science to the clinic","author":"Airley","year":"2009"},{"key":"B66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2016.12.017","article-title":"Efficacy and safety of eribulin as first-to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"32","author":"Maeda","year":"2017","journal-title":"Breast"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0936","article-title":"Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer","volume":"15","author":"O\u2019Shaughnessy","year":"2019","journal-title":"Future Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/cr040478b","article-title":"Formation and repair of interstrand cross-links in DNA","volume":"106","author":"Noll","year":"2006","journal-title":"Chem Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07163-z","article-title":"Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis","volume":"204","author":"Yamaguchi","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1008814","DOI":"10.1080\/2162402X.2015.1008814","article-title":"Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications","volume":"4","author":"Buqu\u00e9","year":"2015","journal-title":"Oncoimmunology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103202","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R&D"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12761","article-title":"Olaparib","volume":"81","author":"Goulooze","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41698-019-0084-3","article-title":"Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types","volume":"3","author":"Ben-Hamo","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"413076","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the management of ovarian cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"BioMed Res Int"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.9.1183","article-title":"Lapatinib in the treatment of breast cancer","volume":"7","author":"Higa","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-267","article-title":"Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells","volume":"13","author":"Chang","year":"2013","journal-title":"BMC Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/bi102059z","article-title":"Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer","volume":"50","author":"Osguthorpe","year":"2011","journal-title":"Biochemistry"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-P1-06-11","article-title":"Abstract P1-06-11: microsatellite instability in triple negative breast cancers","volume":"79","author":"Kurata","year":"2019","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86105","article-title":"The role of taxanes in triple-negative breast cancer: literature review","volume":"9","author":"Mustacchi","year":"2015","journal-title":"Drug Design Dev Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discovery"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0846","article-title":"Emerging therapeutic implications of STK11 mutation: case series","volume":"25","author":"Laderian","year":"2020","journal-title":"Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.28","article-title":"Multigene panel testing in oncology practice: how should we respond","volume":"1","author":"Kurian","year":"2015","journal-title":"JAMA Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.32471\/exp-oncology.2312-8852.vol-43-no-1.15587","article-title":"New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients","volume":"43","author":"Gervas","year":"2021","journal-title":"Exp Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v126.2","article-title":"Patterns of recurrence and metastasis in BRCA1\/BRCA2-associated breast cancers","volume":"126","author":"Song","year":"2020","journal-title":"Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-023-01731-3","article-title":"The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation","volume":"25","author":"Zhang","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/EDBK_280463","article-title":"Genomic alteration in metastatic breast cancer and its treatment","volume":"40","author":"Li","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3013","article-title":"ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1","volume":"16","author":"Zhang","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/genes11111251","article-title":"BARD1 and breast cancer: the possibility of creating screening tests and new preventive and therapeutic pathways for predisposed women","volume":"11","author":"\u015aniadecki","year":"2020","journal-title":"Genes"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205125","article-title":"CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model","volume":"15","author":"Wan","year":"2023","journal-title":"Aging"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e0288482","DOI":"10.1371\/journal.pone.0288482","article-title":"Evaluating the role of MEN1 gene expression and its clinical significance in breast cancer patients","volume":"18","author":"Massey","year":"2023","journal-title":"PloS One"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.20.549745","article-title":"Contrasting roles of different mismatch repair proteins in basal-like breast cancer","author":"Mo","year":"2023","journal-title":"bioRxiv"},{"key":"B106","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41421-023-00614-3","article-title":"Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Discovery"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.916469","article-title":"The potential role of CDH1 as an oncogene combined with related\nmiRNAs and their diagnostic value in breast cancer","volume":"13","author":"Xie","year":"2022","journal-title":"Front\nEndocrinol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.05.013","article-title":"MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy","volume":"514","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2007.06.007","article-title":"Investigate the role of PTEN in chemotaxis of human breast cancer cells","volume":"19","author":"Wan","year":"2007","journal-title":"Cell Signalling"},{"key":"B110","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s42003-020-1092-0","article-title":"STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation","volume":"3","author":"Granado-Mart\u00ednez","year":"2020","journal-title":"Commun Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: An insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0118","article-title":"Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential","volume":"4","author":"Zhuang","year":"2006","journal-title":"Mol Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-014-9745-0","article-title":"Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues","volume":"13","author":"Bashir","year":"2014","journal-title":"Familial Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S350971","article-title":"Comprehensive analysis of the expression and prognosis for RAD51 family in human breast cancer","volume":"15","author":"Shi","year":"2022","journal-title":"Int J Gen Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2916-7","article-title":"miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/bjc.2017.150","article-title":"MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1","volume":"117","author":"Chen","year":"2017","journal-title":"Br J Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"37269","DOI":"10.18632\/oncotarget.v6i35","article-title":"MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","first-page":"28939","DOI":"10.18632\/oncotarget.15960","article-title":"Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation","volume":"8","author":"Drago-Ferrante","year":"2017","journal-title":"Oncotarget"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S199027","article-title":"MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1","volume":"11","author":"Fan","year":"2019","journal-title":"Cancer Manage Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0188-4","article-title":"miR-10b, miR-26a, miR-146a And miR-153 expression in triple negative vs non triple negative breast cancer: potential biomarkers","volume":"23","author":"Fkih M\u2019hamed","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.18632\/aging.102080","article-title":"CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218\/ZFX signaling","volume":"11","author":"Han","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.humpath.2017.08.026","article-title":"Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer","volume":"68","author":"Jang","year":"2017","journal-title":"Hum Pathol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2689-2","article-title":"MicroRNAs in regulation of triple-negative breast cancer progression","volume":"144","author":"Piasecka","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.27","article-title":"MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer","volume":"23","author":"Tang","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2017_206","article-title":"MicroRNA-182 targets FOXF2 to promote the development of triple-negative breast cancer","volume":"64","author":"Yu","year":"2017","journal-title":"Neoplasma"},{"key":"B126","doi-asserted-by":"publisher","first-page":"103196","DOI":"10.1016\/j.critrevonc.2020.103196","article-title":"Triple negative breast cancer in the era of miRNA","volume":"157","author":"Sabit","year":"2021","journal-title":"Crit Rev Oncol\/hematol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv087","article-title":"miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene","volume":"36","author":"Tsouko","year":"2015","journal-title":"Carcinogenesis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.58","article-title":"miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and \u03b11, 3-fucosylated glycans","volume":"6","author":"Zheng","year":"2017","journal-title":"Oncogenesis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"85276","DOI":"10.18632\/oncotarget.19205","article-title":"The microRNAs miR-200b-3p and miR-429-5p target the LIMK1\/CFL1 pathway to inhibit growth and motility of breast cancer cells","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.10.018","article-title":"Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer","volume":"641","author":"Mekala","year":"2018","journal-title":"Gene"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0310-4","article-title":"LncRNA PVT1 regulates triple-negative breast cancer through KLF5\/beta-catenin signaling","volume":"37","author":"Tang","year":"2018","journal-title":"Oncogene"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v120.9","article-title":"LncRNA AWPPH and miRNA-21 regulates cancer cell proliferation and chemosensitivity in triple-negative breast cancer by interacting with each other","volume":"120","author":"Liu","year":"2019","journal-title":"J Cell Biochem"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5951-3","article-title":"microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"B134","first-page":"953","article-title":"miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN","volume":"9","author":"Fang","year":"2017","journal-title":"Am J Trans Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"11641","DOI":"10.18632\/oncotarget.14264","article-title":"MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase","volume":"8","author":"Bayraktar","year":"2017","journal-title":"Oncotarget"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.7150\/thno.82636","article-title":"Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum","volume":"13","author":"Zhao","year":"2023","journal-title":"Theranostics"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e12966","DOI":"10.1111\/cpr.12966","article-title":"The long non-coding RNA landscape in triple-negative breast cancer","volume":"54","author":"Zhang","year":"2021","journal-title":"Cell Proliferation"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S149308","article-title":"Integrative analysis of lncRNAs and miRNAs with coding RNAs associated with ceRNA crosstalk network in triple negative breast cancer","volume":"10","author":"Yuan","year":"2017","journal-title":"OncoTargets Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1\u03b1 signalling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.mbplus.2021.100060","article-title":"The role of the multifaceted long non-coding RNAs: A nuclear-cytosolic interplay to regulate hyaluronan metabolism","author":"Parnigoni","year":"2021","journal-title":"Matrix Biol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41420-022-01174-3","article-title":"Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance","volume":"8","author":"Zhu","year":"2022","journal-title":"Cell Death Discovery"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00901","article-title":"SNHG12: an LncRNA as a potential therapeutic target and biomarker\nfor human cancer","volume":"9","author":"Tamang","year":"2019","journal-title":"Front Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"20420","DOI":"10.1038\/s41598-023-47478-x","article-title":"Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors","volume":"13","author":"Komlosh","year":"2023","journal-title":"Sci Rep"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1533033820980763","DOI":"10.1177\/1533033820980763","article-title":"Long non-coding RNA PVT1 regulates the resistance of the breast cancer cell line MDA-MB-231 to doxorubicin via Nrf2","volume":"19","author":"Luo","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0396-8","article-title":"LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer","volume":"37","author":"Luo","year":"2018","journal-title":"Oncogene"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.997532","article-title":"LncmiRHG-MIR100HG: A new budding star in cancer","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/09168451.2019.1588097","article-title":"LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9","volume":"83","author":"Yang","year":"2019","journal-title":"Biosci Biotechnol Biochem"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.2019.23.issue-5","article-title":"Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"114314","DOI":"10.1016\/j.biopha.2023.114314","article-title":"MIR503HG: A potential diagnostic and therapeutic target in human diseases","volume":"160","author":"Han","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B150","first-page":"533","article-title":"C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer","volume":"9","author":"Wang","year":"2017","journal-title":"Am J Trans Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"67538","DOI":"10.18632\/oncotarget.18733","article-title":"Identification of a novel metastasis inducing lncRNA which suppresses the KAI1\/CD82 metastasis suppressor gene and is upregulated in triple-negative breast cancer","volume":"8","author":"Aram","year":"2017","journal-title":"Oncotarget"},{"key":"B152","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41419-018-0869-2","article-title":"LncRNA MIR100HG promotes cell proliferation in triple-negative breast cancer through triplex formation with p27 loci","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B153","doi-asserted-by":"publisher","first-page":"BSR20181223","DOI":"10.1042\/BSR20181223","article-title":"LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7)","volume":"38","author":"Wang","year":"2018","journal-title":"Biosci Rep"},{"key":"B154","doi-asserted-by":"publisher","first-page":"BSR20190489","DOI":"10.1042\/BSR20190489","article-title":"LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702","volume":"39","author":"Mou","year":"2019","journal-title":"Biosci Rep"},{"key":"B155","doi-asserted-by":"publisher","first-page":"0963689720929983","DOI":"10.1177\/0963689720929983","article-title":"LncRNA DLX6-AS1 contributes to epithelial\u2013mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p\/paxillin axis","volume":"29","author":"Du","year":"2020","journal-title":"Cell Transplant"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.v233.10","article-title":"Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): expression analysis and biological roles research","volume":"233","author":"Wang","year":"2018","journal-title":"J Cell Physiol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmz021","article-title":"LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis","volume":"51","author":"Song","year":"2019","journal-title":"Acta Biochim Biophys Sin"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v120.9","article-title":"LncRNA PTCSC3 inhibits triple-negative breast cancer cell proliferation by downregulating lncRNA H19","volume":"120","author":"Wang","year":"2019","journal-title":"J Cell Biochem"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.2019.23.issue-7","article-title":"LncRNA MIR503HG inhibits cell migration and invasion via miR-103\/OLFM4 axis in triple negative breast cancer","volume":"23","author":"Fu","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B160","article-title":"LncRNA TCONS_l2_00002973 correlates with less advanced tumor stage and favorable survival, and also inhibits cancer cells proliferation while enhancing apoptosis in triple-negative breast cancer","volume":"24","author":"Yan","year":"2019","journal-title":"J Buon"},{"key":"B161","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12038-020-9999-7","article-title":"LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer","volume":"45","author":"Li","year":"2020","journal-title":"J Biosci"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e0158296","DOI":"10.1371\/journal.pone.0158296","article-title":"Integration of breast cancer secretomes with clinical data elucidates potential serum markers for disease detection, diagnosis, and prognosis","volume":"11","author":"Ziegler","year":"2016","journal-title":"PloS One"},{"key":"B163","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.7150\/jca.28032","article-title":"Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer","volume":"9","author":"Kong","year":"2018","journal-title":"J Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/pharmaceutics14122734","article-title":"CD44-receptor targeted gold-doxorubicin nanocomposite for pulsatile chemo-photothermal therapy of triple-negative breast cancer cells","volume":"14","author":"Kalyane","year":"2022","journal-title":"Pharmaceutics"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20141488","article-title":"Soluble CD109 binds TGF-\u03b2 and antagonizes TGF-\u03b2 signalling and responses","volume":"473","author":"Li","year":"2016","journal-title":"Biochem J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2509-5","article-title":"CD109 is a potential target for triple-negative breast cancer","volume":"35","author":"Tao","year":"2014","journal-title":"Tumor Biol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1096\/fsb2fj990934com","article-title":"Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells","volume":"15","author":"Han","year":"2001","journal-title":"FASEB J"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0533-2","article-title":"Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based Cohort Study in Iowa","volume":"16","author":"Lal","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1177\/10668969221126122","article-title":"The diagnostic and prognostic significance of EFEMP1 in breast cancer: an immunohistochemistry study","volume":"31","author":"Fararjeh","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"30034","DOI":"10.18632\/oncotarget.25682","article-title":"The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion","volume":"9","author":"Noonan","year":"2018","journal-title":"Oncotarget"},{"key":"B171","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.3390\/cancers13184521","article-title":"Protein ligands in the secretome of CD36+ fibroblasts induce growth suppression in a subset of breast cancer cell lines","volume":"13","author":"Jabbari","year":"2021","journal-title":"Cancers"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.06.024","article-title":"Fibulin-1 interacts with Sex Hormone Binding Globulin and is linked to less aggressive estrogen-dependent breast cancers","volume":"207","author":"Marano","year":"2018","journal-title":"Life Sci"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207323","article-title":"Immunological and pathobiological roles of fibulin-1 in breast cancer","volume":"23","author":"Pupa","year":"2004","journal-title":"Oncogene"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2019.1607407","article-title":"Tocotrienols modulate breast cancer secretomes and affect cancer-signaling pathways in MDA-MB-231 cells: A label-free quantitative proteomic analysis","volume":"71","author":"Ramdas","year":"2019","journal-title":"Nutr Cancer"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4162","article-title":"Regulation of breast cancer response to chemotherapy by fibulin-1","volume":"67","author":"Pupa","year":"2007","journal-title":"Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.13529","article-title":"Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling","volume":"6","author":"Winiarski","year":"2013","journal-title":"Trans Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00117","article-title":"IGF-binding proteins: why do they exist and why are there so\nmany","volume":"9","author":"Allard","year":"2018","journal-title":"Front Endocrinol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"44062","DOI":"10.18632\/oncotarget.v7i28","article-title":"Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the Malignancy of triple-negative breast cancer","volume":"7","author":"Huber","year":"2016","journal-title":"Oncotarget"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6355","article-title":"CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth","volume":"95","author":"Babic","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1021\/pr500331m","article-title":"Comprehensive N-glycome profiling of cultured human epithelial breast cells identifies unique secretome N-glycosylation signatures enabling tumorigenic subtype classification","volume":"13","author":"Lee","year":"2014","journal-title":"J Proteome Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3892\/ijmm.2015.2395","article-title":"Enhanced expression of polysialic acid correlates with Malignant phenotype in breast cancer cell lines and clinical tissue samples","volume":"37","author":"Wang","year":"2016","journal-title":"Int J Mol Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2020984","DOI":"10.1080\/2162402X.2021.2020984","article-title":"Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer","volume":"11","author":"Zheng","year":"2022","journal-title":"Oncoimmunology"},{"key":"B183","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12291-016-0580-y","article-title":"Cluster of differentiation 44 (CD44) gene variants: a putative cancer stem cell marker in risk prediction of bladder cancer in North Indian population","volume":"32","author":"Verma","year":"2017","journal-title":"Indian J Clin Biochem"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v111.5","article-title":"Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling","volume":"111","author":"Lee","year":"2020","journal-title":"Cancer Sci"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-022-02812-7","article-title":"Involvement of abnormal dystroglycan expression and matriglycan levels in cancer pathogenesis","volume":"22","author":"Quereda","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.10.016","article-title":"Decorin as a multivalent therapeutic agent against cancer","volume":"97","author":"Neill","year":"2016","journal-title":"Advanced Drug Delivery Rev"},{"key":"B187","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3390\/ijms24032100","article-title":"Proteins found in the triple-negative breast cancer secretome and their therapeutic potential","volume":"24","author":"McHenry","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2246322","DOI":"10.1080\/2162402X.2023.2246322","article-title":"TNBC-derived Gal3BP\/Gal3 complex induces immunosuppression through CD45 receptor","volume":"12","author":"Raiter","year":"2023","journal-title":"OncoImmunology"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.883998","article-title":"Lysyl oxidases expression and breast cancer progression: A\nbioinformatic analysis","volume":"13","author":"Ramos","year":"2022","journal-title":"Front Pharmacol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.amsu.2014.06.014","article-title":"The ubiquitous neural cell adhesion molecule (N-CAM)","volume":"3","author":"Weledji","year":"2014","journal-title":"Ann Med Surg"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11569","article-title":"P4HB modulates epithelial\u2212mesenchymal transition and the \u03b2\u2212catenin\/snail pathway influencing chemoresistance in liver cancer cells","volume":"20","author":"Ma","year":"2020","journal-title":"Oncol Lett"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1145407","article-title":"Polyphyllin I suppresses the gastric cancer growth by promoting\ncancer cell ferroptosis","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.925298","article-title":"Reelin promotes cisplatin resistance by induction of epithelial-mesenchymal transition via p38\/gsk3\u03b2\/snail signaling in non-small cell lung cancer","volume":"26","author":"Li","year":"2020","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"key":"B194","doi-asserted-by":"publisher","first-page":"216221","DOI":"10.1016\/j.canlet.2023.216221","article-title":"Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function","volume":"565","author":"Ren","year":"2023","journal-title":"Cancer Lett"},{"key":"B195","doi-asserted-by":"publisher","first-page":"e68481","DOI":"10.7554\/eLife.68481.sa2","article-title":"Binding blockade between TLN1 and integrin \u03b21 represses triple-negative breast cancer","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"},{"key":"B196","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1038\/s41467-020-17395-y","article-title":"Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"B197","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3390\/ijms20112767","article-title":"TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B198","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5306\/wjco.v5.i3.311","article-title":"Epithelial-mesenchymal transition transcription factors and miRNAs:\u201cPlastic surgeons\u201d of breast cancer","volume":"5","author":"Moyret-Lalle","year":"2014","journal-title":"World J Clin Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4361-7","article-title":"Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers","volume":"37","author":"Scimeca","year":"2016","journal-title":"Tumor Biol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.90","article-title":"Mechanisms of the epithelial\u2013mesenchymal transition by TGF-\u03b2","volume":"5","author":"Wendt","year":"2009","journal-title":"Future Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03398-6","article-title":"TGF\u03b2-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer","volume":"77","author":"Hua","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-010-9181-1","article-title":"The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-\u03b2 in normal and Malignant mammary epithelial cells","volume":"15","author":"Taylor","year":"2010","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2012.05.010","article-title":"Post-translational regulation of TGF-\u03b2 receptor and Smad signaling","volume":"586","author":"Xu","year":"2012","journal-title":"FEBS Lett"},{"key":"B204","doi-asserted-by":"publisher","first-page":"e35684","DOI":"10.1371\/journal.pone.0035684","article-title":"Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer","volume":"7","author":"Wu","year":"2012","journal-title":"PloS One"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.5","article-title":"TGF-\u03b2-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res"},{"key":"B206","doi-asserted-by":"publisher","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-Smad signaling pathways of the TGF-\u03b2 family","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00711","article-title":"Wnt, Notch, and TGF-\u03b2 pathways impinge on hedgehog signaling\ncomplexity: an open window on cancer","volume":"10","author":"Pelullo","year":"2019","journal-title":"Front Genet"},{"key":"B209","doi-asserted-by":"publisher","first-page":"134","DOI":"10.18632\/genesandcancer.v10i5-6","article-title":"Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-\u03b2 from growth suppressor to growth and metastasis promoter through TMEPAI\/PMEPA1 in triple negative breast cancer","volume":"10","author":"Singha","year":"2019","journal-title":"Genes Cancer"},{"key":"B210","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-021-00375-w","article-title":"Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1","volume":"8","author":"Sun","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer"},{"key":"B212","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4161\/org.4.2.5851","article-title":"Wnt signal transduction pathways","volume":"4","author":"Komiya","year":"2008","journal-title":"Organogenesis"},{"key":"B213","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev Cell"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B215","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.7150\/thno.47717","article-title":"Glycogen synthase kinase-3\u03b2: a promising candidate in the fight against fibrosis","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"},{"key":"B216","doi-asserted-by":"publisher","first-page":"e17083","DOI":"10.1371\/journal.pone.0017083","article-title":"An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer","volume":"6","author":"Katz","year":"2011","journal-title":"PloS One"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.205","article-title":"[amp]]beta;-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation","volume":"24","author":"Geyer","year":"2011","journal-title":"Modern Pathol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of Malignant and stem cell traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.150","article-title":"The many faces and functions of \u03b2-catenin","volume":"31","author":"Valenta","year":"2012","journal-title":"EMBO J"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.4161\/cc.29765","article-title":"[amp]]alpha;-catenin: A tumor suppressor beyond adherens junctions","volume":"13","author":"Sun","year":"2014","journal-title":"Cell Cycle"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.2174\/15680096113136660101","article-title":"Regulation of EMT by Notch signaling pathway in tumor progression","volume":"13","author":"Li","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2011.08.005","article-title":"Notch signaling and Notch signaling modifiers","volume":"43","author":"Wang","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"8707053","DOI":"10.1155\/2019\/8707053","article-title":"Notch signaling activation as a hallmark for triple-negative breast cancer subtype","volume":"2019","author":"Giuli","year":"2019","journal-title":"J Oncol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1535-7163.MCT-10-0677","article-title":"Notch signaling pathway as a therapeutic target in breast cancer","volume":"10","author":"Al-Hussaini","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.230","article-title":"Notch3: from subtle structural differences to functional diversity","volume":"27","author":"Bellavia","year":"2008","journal-title":"Oncogene"},{"key":"B226","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/genes10120961","article-title":"A \u201cNOTCH\u201d deeper into the epithelial-to-mesenchymal transition (EMT) program in breast cancer","volume":"10","author":"Kar","year":"2019","journal-title":"Genes"},{"key":"B227","doi-asserted-by":"publisher","first-page":"61036","DOI":"10.18632\/oncotarget.11062","article-title":"NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/BD-220041","article-title":"Clinical significance of Notch receptors in triple negative breast cancer","volume":"42","author":"Shah","year":"2023","journal-title":"Breast Dis"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.2174\/138945010791170860","article-title":"The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness","volume":"11","author":"Wang","year":"2010","journal-title":"Curr Drug Targets"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1549","article-title":"Notch signaling induces EMT in OSCC cell lines in a hypoxic environment","volume":"6","author":"Ishida","year":"2013","journal-title":"Oncol Lett"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802047105","article-title":"Notch signaling mediates hypoxia-induced tumor cell migration and invasion","volume":"105","author":"Sahlgren","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B232","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B233","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.3390\/cells11182872","article-title":"Notch3 transactivates glycogen synthase kinase-3-beta and inhibits epithelial-to-mesenchymal transition in breast cancer cells","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"B234","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41420-023-01450-w","article-title":"Silencing Notch4 promotes tumorigenesis and inhibits metastasis of triple-negative breast cancer via Nanog and Cdc42","volume":"9","author":"Tian","year":"2023","journal-title":"Cell Death Discovery"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2415489","article-title":"The notch pathway in breast cancer progression","volume":"2018","author":"Kontomanolis","year":"2018","journal-title":"Sci World J"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3123","article-title":"Epithelial\u2013mesenchymal transition induced by TNF-\u03b1 requires NF-\u03baB\u2013mediated transcriptional upregulation of Twist1","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00584","article-title":"Tumor necrosis factor \u03b1 blockade: an opportunity to tackle\nbreast cancer","volume":"10","author":"Mercogliano","year":"2020","journal-title":"Front Oncol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.286","article-title":"Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression","volume":"36","author":"Xu","year":"2017","journal-title":"Oncogene"},{"key":"B239","article-title":"Targeting the NF\u03baB signaling pathways for breast cancer prevention and therapy","volume":"22","author":"Wang","year":"2015","journal-title":"Curr Medicinal Chem"},{"key":"B240","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/diagnostics8030059","article-title":"The interplay between circulating tumor cells and the immune system: from immune escape to cancer immunotherapy","volume":"8","author":"Leone","year":"2018","journal-title":"Diagnostics"},{"key":"B241","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cells5020016","article-title":"The NF-\u03baB pathway and cancer stem cells","volume":"5","author":"Rinkenbaugh","year":"2016","journal-title":"Cells"},{"key":"B242","doi-asserted-by":"publisher","first-page":"60684","DOI":"10.18632\/oncotarget.19527","article-title":"The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy","volume":"8","author":"Armas-L\u00f3pez","year":"2017","journal-title":"Oncotarget"},{"key":"B243","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/cells8020147","article-title":"Gli proteins: regulation in development and cancer","volume":"8","author":"Niewiadomski","year":"2019","journal-title":"Cells"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-014-0444-4","article-title":"Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF\u03baB) pathway","volume":"16","author":"Colavito","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B245","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.3390\/ijms21186863","article-title":"The role of smoothened in cancer","volume":"21","author":"Jeng","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp048","article-title":"Hedgehog signalling in breast cancer","volume":"30","author":"Kasper","year":"2009","journal-title":"Carcinogenesis"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.4161\/19336918.2014.983794","article-title":"Reprogramming during epithelial to mesenchymal transition under the control of TGF\u03b2","volume":"9","author":"Tan","year":"2015","journal-title":"Cell Adhesion Migration"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"B249","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.1.306-319.2004","article-title":"Snail mediates E-cadherin repression by the recruitment of the Sin3A\/histone deacetylase 1 (HDAC1)\/HDAC2 complex","volume":"24","author":"Peinado","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.141","article-title":"\u03b2-catenin\/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast","volume":"23","author":"Lacroix-Triki","year":"2010","journal-title":"Modern Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1431418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T08:00:18Z","timestamp":1728547218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1431418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":251,"alternative-id":["10.3389\/fonc.2024.1431418"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1431418","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"article-number":"1431418"}}